The first phase III trial to test perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma yielded highly promising results, leading to regulatory approvals of adjuvant pembrolizumab. However, subsequent phase III trials, including the IMmotion010 trial of adjuvant atezolizumab, did not demonstrate similar benefits. Although molecular biomarkers are urgently needed to better delineate responder subgroups, the unique design of each trial might partially explain some of the patterns identified.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
Powles, T. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 1133–1144 (2022).
Pal, S. K. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400, 1103–1116 (2022).
Motzer, R. J. et al. LBA4 adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase III CheckMate 914 trial. Ann. Oncol. 33, S1430 (2022).
Allaf, M. et al. LBA67 phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann. Oncol. 33, S1432–S1433 (2022).
Zoumpourlis, P., Genovese, G., Tannir, N. M. & Msaouel, P. Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin. Genitourin. Cancer 19, 103–116 (2021).
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
McDermott, D. F. et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J. Clin. Oncol. 39, 1020–1028 (2021).
Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432–437 (2021).
Correa, A. et al. Presence of circulating tumour DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis. Ann. Oncol. 30, v32 (2019).
The work of T.K.C. is supported in part by Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program (5P30CA006516-56) grants, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute.
C.L. has received grants from Genentech/imCORE. T.K.C. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, and Up-To-Date, and for CME events from Peerview, OncLive, MJH and others, outside of the submitted work; institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA; equity in Osel, Pionyr, Precede Bio, and Tempest; committee membership for ACCRU, ASCO, ESMO, KidneyCan and the NCCN GU Steering Committee; medical writing and editorial assistance support that might have been funded in part by communications companies; mentorship of several non-US citizens on research projects with potential funding, in part, from non-US sources/foreign components. The institution of C.L. and T.K.C. (Dana-Farber Cancer Institute) might have received additional independent funding from pharmaceutical companies and/or royalties potentially involved in research around the subject matter.
About this article
Cite this article
Labaki, C., Choueiri, T.K. Perioperative immunotherapy for renal cell carcinoma: looking beyond the data. Nat Rev Clin Oncol (2022). https://doi.org/10.1038/s41571-022-00710-5